Advanced search
Publication Cover
OncoImmunology Volume 10, 2021 - Issue 1
Submit an article Journal homepage
3,496
Views
29
CrossRef citations to date
0
Altmetric
Original Research

A multicenter characterization of hepatitis associated with immune checkpoint inhibitors

J. Randall Patrinely Jr.a Department of Medicine, School of Medicine, Vanderbilt University, Nashville, Tennessee, USAORCID Iconhttps://orcid.org/0000-0002-0979-1625View further author information
ORCID Icon,
Ben McGuiganb Melanoma Institute Australia, the University of Sydney, Sydney, New South Wales, AustraliaView further author information
,
Sunandana Chandrac From the Division of Hematology/Oncology, Northwestern Feinberg School of Medicine, Chicago, Illinois, USAView further author information
,
Sarah E. Fentonc From the Division of Hematology/Oncology, Northwestern Feinberg School of Medicine, Chicago, Illinois, USAView further author information
,
Akansha Chowdharyc From the Division of Hematology/Oncology, Northwestern Feinberg School of Medicine, Chicago, Illinois, USAView further author information
,
Lucy B. Kennedyd Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, USAView further author information
,
Meghan J. Mooradiane Department of Medical Oncology, Massachusetts General Hospital, Boston, Massachusetts, USAView further author information
,
Marisa Palmerif Department of Medicine, Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, New Jersey, USAView further author information
,
Daniella Portalf Department of Medicine, Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, New Jersey, USAView further author information
,
Sara N. Horstg Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USAView further author information
,
Elizabeth A. Scovilleg Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USAView further author information
,
Georgina V. Longb Melanoma Institute Australia, the University of Sydney, Sydney, New South Wales, AustraliaORCID Iconhttps://orcid.org/0000-0001-8894-3545View further author information
ORCID Icon,
Chanjuan Shih Department of Pathology, Duke University Medical Center, Durham, NC, USAView further author information
,
Janice M. Mehnertf Department of Medicine, Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, New Jersey, USAView further author information
,
Ryan J. Sullivane Department of Medical Oncology, Massachusetts General Hospital, Boston, Massachusetts, USAView further author information
,
April K. Salamad Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, USAView further author information
,
Jeffrey A. Sosmanc From the Division of Hematology/Oncology, Northwestern Feinberg School of Medicine, Chicago, Illinois, USAView further author information
,
Alexander M. Menziesb Melanoma Institute Australia, the University of Sydney, Sydney, New South Wales, Australia;i Department of Medical Oncology, Royal North Shore and Mater Hospitals, the University of Sydney, Sydney, New South Wales, AustraliaView further author information
&
Douglas B. Johnsong Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USACorrespondence[email protected]
View further author information
 show all
Article: 1875639 | Received 04 Nov 2020, Accepted 08 Jan 2021, Published online: 08 Feb 2021

Citations (29)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Syed B Ali, Preethi Vembar, Shawgi Sukumaran, Dimuth Gunawardane, Tiffany Hughes & Anthony Smith. (2023) Tocilizumab in Grade 4 Hepatitis Secondary to Immune Checkpoint Inhibitor: A Case Report and Review of the Literature. Immunotherapy 15:14, pages 1125-1132.
Read now
Filip Stefanovic, Andres Gomez-Caminero, David M Jacobs, Poornima Subramanian, Igor Puzanov, Maya R Chilbert, Steven G Feuerstein, Yan Yatsynovich, Benjamin Switzer & Jerome J Schentag. (2022) Neural Net Modeling of Checkpoint Inhibitor Related Myocarditis and Steroid Response. Clinical Pharmacology: Advances and Applications 14, pages 69-90.
Read now

Articles from other publishers (27)

Alisa Likhitsup & Robert J. Fontana. (2024) Diagnosis and management of immune mediated liver injury from checkpoint inhibitors. Current Opinion in Gastroenterology 40:3, pages 164-171.
Crossref
Mar Riveiro-Barciela, Sabela Carballal, Álvaro Díaz-González, Míriam Mañosa, Javier Gallego-Plazas, Joaquín Cubiella, Paula Jiménez-Fonseca, María Varela, Luis Menchén, Bruno Sangro, Ana Fernández-Montes, Francisco Mesonero, Miguel Ángel Rodríguez-Gandía, Fernando Rivera & María-Carlota Londoño. (2024) Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU. Gastroenterología y Hepatología 47:4, pages 401-432.
Crossref
Xu Tong, Tao Zhan, Xiaoqin Dong & Dong Xu. (2024) Fever of unknown origin associated with immune checkpoint inhibitors. Frontiers in Immunology 15.
Crossref
Mar Riveiro-Barciela, Sabela carballal, Álvaro Díaz-González, Miriam Mañosa, Javier Gallgo-Plazas, Joaquín Cubiella, Paula Jiménez-Fonseca, María Varela, Luis Menchén, Bruno Sangro, Ana Fernández-Montes, Francisco Mesonero, Miguel Ángel Rodríguez-Gandía, Fernando Rivera & María-Carlota Londoño. (2024) Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH-AEG-SEPD-SEOM-GETECCU. Revista Española de Enfermedades Digestivas.
Crossref
Eveline Daetwyler, Till Wallrabenstein, David König, Laura C Cappelli, Jarushka Naidoo, Alfred Zippelius & Heinz Läubli. (2024) Corticosteroid-resistant immune-related adverse events: a systematic review. Journal for ImmunoTherapy of Cancer 12:1, pages e007409.
Crossref
J.A. Velarde-Ruiz Velasco, D.K. Tapia Calderón, S. Cerpa-Cruz, J.A. Velarde-Chávez, J.F. Uribe Martínez, E.S. García Jiménez, J.M. Aldana Ledesma, Á. Díaz-González & J. Crespo. (2024) Immune-mediated hepatitis: Basic concepts and treatment. Revista de Gastroenterología de México (English Edition) 89:1, pages 106-120.
Crossref
J.A. Velarde-Ruiz Velasco, D.K. Tapia Calderón, S. Cerpa-Cruz, J.A. Velarde-Chávez, J.F. Uribe Martínez, E.S. García Jiménez, J.M. Aldana Ledesma, Á. Díaz-González & J. Crespo. (2024) Hepatitis inmunomediada: conceptos básicos y tratamiento. Revista de Gastroenterología de México 89:1, pages 106-120.
Crossref
Anh T. TranJames J. CrawfordDebashis MandalTezcan GuneyJamie Karmel. 2023. 2023 Medicinal Chemistry Reviews. 2023 Medicinal Chemistry Reviews 473 500 .
Erica M. Storm, Dimitrios Makrakis, Genevieve I. Lin, Rafee Talukder, Dimitra R. Bakaloudi, Eshana E. Shah, Iris W. Liou, David Hockenbery, Petros Grivas & Ali Raza Khaki. (2023) Role of Underlying Liver Pathology in the Development of Immune-Related Hepatitis: A Case–Control Study. Targeted Oncology 18:4, pages 601-610.
Crossref
Lina Hountondji, Christophe Ferreira De Matos, Fanny Lebossé, Xavier Quantin, Candice Lesage, Pascale Palassin, Valérian Rivet, Stéphanie Faure, Georges-Philippe Pageaux, Éric Assenat, Laurent Alric, Amel Zahhaf, Dominique Larrey, Philine Witkowski Durand Viel, Benjamin Riviere, Selves Janick, Stéphane Dalle, Alexandre Thibault Jacques Maria, Thibaut Comont & Lucy Meunier. (2023) Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort. JHEP Reports 5:6, pages 100719.
Crossref
Kefan Chen, Junhao He, Jing Xu & Jie Chen. (2023) Effectiveness of immunosuppressant use for the treatment of immune checkpoint inhibitor-induced liver injury: A systematic review and meta-analysis. Frontiers in Oncology 13.
Crossref
Jarushka Naidoo, Catherine Murphy, Michael B Atkins, Julie R Brahmer, Stephane Champiat, David Feltquate, Lee M Krug, Javid Moslehi, M Catherine Pietanza, Joanne Riemer, Caroline Robert, Elad Sharon, Maria E Suarez-Almazor, Karthik Suresh, Michelle Turner, Jeffrey Weber & Laura C Cappelli. (2023) Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology. Journal for ImmunoTherapy of Cancer 11:3, pages e006398.
Crossref
Hui Xing, Yang Wang, Bo Qu, Qiang Wei, Cuihua Li, Chao Pan & Hui Li. (2023) The Current status of steroid-refractory immune-checkpoint-inhibitor-related hepatotoxicity. Translational Oncology 28, pages 101619.
Crossref
Christopher Fan, Ahyoung Kim, Sean Li, Jarushka Naidoo, Laura C. Cappelli, Julie R. Brahmer, Robert A. Anders & Amy K. Kim. (2022) Outcomes of immunotherapy-related hepatotoxicity from a multi-disciplinary toxicity team. Journal of Cancer Research and Clinical Oncology 149:2, pages 877-883.
Crossref
Zherui Liu, Yun Zhu, Huan Xie & Zhengsheng Zou. (2023) Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives. Frontiers in Pharmacology 13.
Crossref
Liqiu Kou, Qinglian Wen, Xiaolu Xie, Xiu Chen, Jun Li & Yaling Li. (2022) Adverse events of immune checkpoint inhibitors for patients with digestive system cancers: A systematic review and meta-analysis. Frontiers in Immunology 13.
Crossref
Benjamin C. Park, Aaron X. T. Lee, Fei Ye, Isik Turker & Douglas B. Johnson. (2022) Immune checkpoint inhibitors and their impact on liver enzymes and attenuation. BMC Cancer 22:1.
Crossref
Caroline Plazy, Dalil Hannani & Elisa Gobbini. (2022) Immune Checkpoint Inhibitor Rechallenge and Resumption: a Systematic Review. Current Oncology Reports 24:9, pages 1095-1106.
Crossref
Masayuki Ueno, Hiroyuki Takabatake, Ayako Hata, Takahisa Kayahara, Youichi Morimoto, Kenji Notohara & Motowo Mizuno. (2022) Mycophenolate mofetil for immune checkpoint inhibitor‐related hepatotoxicity relapsing during dose reduction of corticosteroid: A report of two cases and literature review. Cancer Reports 5:9.
Crossref
James H. Lewis, Sophia K. Khaldoyanidi, Carolyn D. Britten, Andrew H. Wei & Marion Subklewe. (2022) Clinical Significance of Transient Asymptomatic Elevations in Aminotransferase (TAEAT) in Oncology. American Journal of Clinical Oncology 45:8, pages 352-365.
Crossref
Alice Tew, Leila Khoja, Lalit Pallan & Neil Steven. (2022) Management of immune-related hepatitis in patients being treated with checkpoint inhibitors for metastatic melanoma, a review and case series. Journal of Oncology Pharmacy Practice, pages 107815522211035.
Crossref
Douglas B. Johnson, Caroline A. Nebhan, Javid J. Moslehi & Justin M. Balko. (2022) Immune-checkpoint inhibitors: long-term implications of toxicity. Nature Reviews Clinical Oncology 19:4, pages 254-267.
Crossref
Marion Allouchery, Clément Beuvon, Marie-Christine Pérault-Pochat, Pascal Roblot, Mathieu Puyade & Mickaël Martin. (2022) Safety of Immune Checkpoint Inhibitor Resumption after Interruption for Immune-Related Adverse Events, a Narrative Review. Cancers 14:4, pages 955.
Crossref
Meagan-Helen Henderson Berg, Sonia Victoria del Rincón & Wilson H Miller. (2022) Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition. Journal for ImmunoTherapy of Cancer 10:1, pages e003551.
Crossref
Hao Chi Zhang, Lan Sun Wang & Ethan Miller. 2022. Managing Immunotherapy Related Organ Toxicities. Managing Immunotherapy Related Organ Toxicities 119 165 .
Joseph William Clinton, Sara Kiparizoska, Soorya Aggarwal, Stephanie Woo, William Davis & James H. Lewis. (2021) Drug-Induced Liver Injury: Highlights and Controversies in the Recent Literature. Drug Safety 44:11, pages 1125-1149.
Crossref
Ankit Jain, Shivakumar Chitturi, Geoffrey Peters & Desmond Yip. (2021) Atezolizumab and bevacizumab as first line therapy in advanced hepatocellular carcinoma: Practical considerations in routine clinical practice. World Journal of Hepatology 13:9, pages 1132-1142.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.